Brief: Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough
20/05/2025 12:09
May 20 (Reuters) - Trevi Therapeutics Inc TRVI.O: TREVI THERAPEUTICS ANNOUNCES ADDITIONAL ANALYSES FROM PHASE 2A RIVER TRIAL OF HADUVIO IN PATIENTS WITH REFRACTORY CHRONIC COUGH Source text: ID:nPn2pbKB7a Further company coverage: TRVI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million